Searchable abstracts of presentations at key conferences in endocrinology

ea0075m08 | Metabolic Bone | EYES2021

Safety and efficacy of PTH 1-34 and 1-84 therapy in chronic hypoparathyroidism: a meta-analysis of prospective trials

Hasenmajer Valeria , Puliani Giulia , Sada Valentina , Tarantino Chiara , Lenzi Andrea , Isidori Andrea

Introduction: Hypoparathyroidism is the only endocrine deficiency for which replacement therapy with the missing hormone is not part of the clinical practice. High quality evidence on the use of PTH 1-34 or PTH 1-84 in hypoparathyroidism is missing.Objective: We aim to evaluate the efficacy and safety of PTH 1-34 and PTH 1-84, and to compare the two treatments when possible.Methods: We searched databases up to March 2021 for random...

ea0063p453 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a case-control study from NETTARE Unit

Feola Tiziana , Sesti Franz , Puliani Giulia , Sbardella Emilia , Cozzolino Alessia , Lenzi Andrea , Faggiano Antongiulio , Isidori Andrea M , Giannetta Elisa

Introduction: GEP-NENs represent a heterogeneous group of neoplasms with increasing incidence in the last years. Pathogenesis and risk factors of sporadic GEP-NENs are not clear and still debated. The aim of this study is to evaluate the main risk factors for sporadic GEP-NENs in patients followed by the NETTARE Unit (NeuroEndocrine TAsk force of of ‘Sapienza’ University of Rome).Methods: We performed a case-control study including 32 consecuti...

ea0049ep1050 | Pituitary - Clinical | ECE2017

Effects of somatostatin analogs on glucose metabolism in acromegalic patients: a meta-analysis of prospective interventional studies

Feola Tiziana , Cozzolino Alessia , Simonelli Ilaria , Sbardella Emilia , Puliani Giulia , Giannetta Elisa , Pasqualetti Patrizio , Lenzi Andrea , Isidori Andrea M

Introduction: Glucose metabolism impairment is a common complication of acromegaly. Somatostatin analogs (SSAs) are used as both first and second line treatment. The effect of SSAs on glucose metabolism in acromegaly is still debated.Aim: To address the following questions: 1) do SSAs affect glucose metabolism? 2) does the effect correlate with disease control? 3) do different SSAs – Lanreotide (LAN) and octreotide LAR (OCT) – affect metabolism...

ea0049ep1054 | Pituitary - Clinical | ECE2017

Quantitative analysis of the pituitary gland at magnetic resonance imaging in obese patients

Puliani Giulia , Lubrano Carla , Fiorelli Marco , Sbardella Emilia , Graziadio Chiara , Gianfrilli Daniele , Lenzi Andrea , Isidori Andrea M

Background: Hypothalamic-pituitary function and adipose tissue are deeply interconnected. Obesity has been linked to morpho-functional changes in several endocrine glands (thyroid, adrenal, gonads). No study has quantified the appearance of the pituitary gland in obese subjects.Aim: To measure pituitary signal intensity, homogeneity and texture of the pituitary gland at magnetic resonance (MR) in obese subjects free of focal pituitary disease.<p clas...

ea0081p390 | Endocrine-Related Cancer | ECE2022

Uncovering the immune profile in well-differentiated gastroenteropancreatic neuroendocrine tumors

Sesti Franz , Puliani Giulia , Sciarra Francesca , Feola Tiziana , Centello Roberta , Di Vito Valentina , Pandozzi Carla , Lenzi Andrea , Isidori Andrea , Venneri Mary Anna , Faggiano Antongiulio , Giannetta Elisa

Introduction: Immune tumor microenvironment plays a key role in tumors’ growth and metastatic spread, while its role in the heterogeneous field of neuroendocrine neoplasms (NENs) remains unclear. There is evidence that tumor progression in NENs is promoted by an immunosuppressed microenvironment created by a plethora of infiltrating immune cells. Changes in circulating leukocyte and peripheral blood mononuclear cell (PBMC) subpopulations can mirror the local alteration of...

ea0090p278 | Adrenal and Cardiovascular Endocrinology | ECE2023

Bone metabolism and dual-release Hydrocortisone: results from a real-life study

Ferrari Davide , Sada Valentina , Hasenmajer Valeria , De Alcubierre Dario , Puliani Giulia , Minnetti Marianna , Cozzolino Alessia , Bonaventura Ilaria , Tomaselli Alessandra , Pofi Riccardo , Lenzi Andrea , M. Isidori Andrea

Background: Patients with adrenal insufficiency (AI) require long-term glucocorticoid (GC) replacement therapy and generally show an increased prevalence of bone metabolism alterations. Only few data are available on bone safety of dual-release Hydrocortisone (DR-HC) therapy.Objective: To evaluate bone metabolism in both primary AI (PAI) and secondary AI (SAI) during long-term therapy with DR-HC.Methods: We studied patients with AI...

ea0090p423 | Pituitary and Neuroendocrinology | ECE2023

Immune profile in acromegalic patients and the impact of the current medical treatment. Resultsfrom the PROMISE study

Feola Tiziana , De Alcubierre Dario , Sada Valentina , Puliani Giulia , Sciarra Francesca , Cozzolino Alessia , Appetecchia Marialuisa , Sbardella Emilia , Jaffrain-Rea Marie-Lise , Anna Venneri Mary , Isidori Andrea

Context: Acromegaly is associated with several metabolic and cardio-respiratory comorbidities, with a relative increase in the last years of cancer mortality. Although the GH/ IGF-1 axis has long been supposed to play a role on immune modulation, immune function in acromegaly is poorly known.Objective: This observational, prospective, single site, pilot study (NCT05069324) aims to analyse peripheral blood mononuclear cells (PBMCs) subpopulations in acrom...

ea0063p450 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Prognostic role of angiogenesis-associated factors Tie2 and Angiopoietin 2 in patients with neuroendocrine neoplasms: The NETTARE Unit experience

Puliani Giulia , Sesti Franz , Feola Tiziana , Sbardella Emilia , Cozzolino Alessia , Pofi Riccardo , Faggiano Antongiulio , Lenzi Andrea , Anastasi Emanuela , Venneri Mary A , Giannetta Elisa , Isidori Andrea M

Introduction: The role of Angiopoietin (Ang)/Tie2 kinase pathway in neuroendocrine neoplasms (NENs) has recently received increasing attention, but its clinical role remains unclear. Tie2-receptor inactivation favours chronic inflammation. The balance between its agonist and antagonist regulates its signalling. Aim of this study was to measure serum soluble Tie2 (sTie2) and Ang-2 in patients followed at the NETTARE Unit (NeuroEndocrine TAsk foRcE of ‘Sapienza’ Univer...

ea0056oc13.4 | The curious case of growth hormone | ECE2018

Effects of pegvisomant on glucose metabolism in acromegaly: A meta-analysis of prospective interventional studies

Feola Tiziana , Cozzolino Alessia , Puliani Giulia , Sbardella Emilia , Gianfrilli Daniele , Hasenmajer Valeria , Simonelli Ilaria , Pasqualetti Patrizio , Lenzi Andrea , Isidori Andrea M.

Introduction: Glucose metabolism impairment is a common complication of acromegaly. Pegvisomant (PEG) is used as second-line medical treatment in acromegaly. Data from literature suggest a positive effect of PEG on glucose metabolism but a meta-analysis has never been performed.Aim: To address the following questions: i) does PEG affect glucose metabolism? ii) does the effect correlate with disease control?Methods: We performed a m...

ea0056p873 | Pituitary - Clinical | ECE2018

Pituitary intensity at magnetic resonance imaging is reduced in obese patients: results from the CHIASM study

Puliani Giulia , Sbardella Emilia , Cozzolino Alessia , Pozza Carlotta , Feola Tiziana , Gianfrilli Daniele , Lubrano Carla , Fiorelli Marco , Lenzi Andrea , Isidori Andrea M

Introduction: Even if obesity has been associated to several hormonal imbalances, pituitary appearance at Magnetic Resonance Imaging (MRI) in obese patients is understudied.Aim: To measure pituitary signal intensity and homogeneity at MRI in obese subjects free of focal pituitary disease, in the context of the CHIasM study (Changes in the Hypotalamic-pItuitary region of patients with Metabolic syndrome and obesity).Materials and me...